Negative or Null Peptide Evidence

In peptide marketing, the loudest claims are usually positive. The quietest, but often most informative, are the null findings and failed replications.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Why negative findings matter

• They tell us a claimed effect did not show up in a particular model.
• They constrain how confidently a positive finding can be generalised.
• They protect against the “file-drawer” problem — selectively publishing only positive results.

Publication bias

Positive results are easier to publish than null results. Over time this skews the visible literature in favour of effect-finding, even when the true rate of effect-finding is lower. Meta-analyses that adjust for publication bias often find smaller effect sizes than the raw literature suggests.

Failed replications

Single-lab findings, especially in preclinical peptide research, sometimes do not replicate. Where a body of evidence rests on a single laboratory’s work, that is a known weakness — even when the original studies are well-conducted.

‘No evidence’ vs ‘evidence of no effect’

These are different things. “No evidence” means no one has looked, or no one has published. “Evidence of no effect” means someone looked carefully and found nothing. The former does not imply safety.

How this site treats null and negative findings

Where a peptide claim is contested or has failed replication, we flag it. Where the literature on a peptide is dominated by a single laboratory, we say so on the relevant page (for example, the BPC-157 Sikiric-lab citation pattern).